Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. - Wikidata - wikimedia - TriplyDB

Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.

Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.

http://www.wikidata.org/entity/Q44680981

about

Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression Modes of resistance to anti-angiogenic therapy Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update Structures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma The Foxc2 transcription factor regulates tumor angiogenesis Modulation of Autophagy by Sorafenib: Effects on Treatment Response Vascular Wall-Resident Multipotent Stem Cells of Mesenchymal Nature within the Process of Vascular Remodeling: Cellular Basis, Clinical Relevance, and Implications for Stem Cell Therapy Profile of nintedanib in the treatment of solid tumors: the evidence to date Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization Brain tumor-targeted drug delivery strategies Targeting angiogenesis in squamous non-small cell lung cancer Signaling pathways in the development of infantile hemangioma Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor Adaptation to antiangiogenic therapy in neurological tumors Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting Fit for the Eye: Aptamers in Ocular Disorders Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.Sustained delivery of a HIF-1 antagonist for ocular neovascularization.Physical supports from liver cancer cells are essential for differentiation and remodeling of endothelial cells in a HepG2-HUVEC co-culture model.Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo.Phase I Trial of Cediranib in combination with cisplatin and pemetrexed in chemo naive patients with unresectable malignant pleural mesothelioma (SWOG S0905).Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib.Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas.Platelet-derived growth factor-B normalizes micromorphology and vessel function in vascular endothelial growth factor-A-induced squamous cell carcinomas A dual-targeting PDGFRbeta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo.Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma.Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Investigational agents in development for the treatment of ovarian cancer Clinical impact of tumour biology in the management of gastroesophageal cancer Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure Vascular-targeted photothermal therapy of an orthotopic murine glioma model.Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy.Targeting angiogenesis in advanced cervical cancer.Targeting the PDGF signaling pathway in tumor treatment Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.

P2860

Q24595357-441B9F79-7ADB-4D10-A7E3-2A15BA2D5AAE Q24608005-605C6EE6-97CE-4703-8B4D-63C814AEE277 Q24619987-E1491D45-65CB-4744-989C-0A4C657425FC Q24623888-E6E6B5EE-0590-489A-9362-9490371F4D51 Q24632791-59E418E6-F14C-43EE-A179-B20FEAFDE186 Q24647592-DE0F21A8-218A-4975-A353-48EA980216BA Q26745320-70EF4448-07D6-4469-9314-DE153D8B3394 Q26765919-41B48EA8-8B4C-41BB-A34B-35452D2792A5 Q26775134-C1478CF5-BF93-4F2D-A163-18D0523278FA Q26781833-95458602-3D58-4F2C-A455-3C7F51D6341B Q26829741-315B9A11-ADEE-4594-872B-3CAE41033119 Q26861341-34EE9F4F-BA4C-4833-AAB2-D796DDB0B7B7 Q26996608-3823E4A2-7484-4589-8E06-99D13532F814 Q27024235-F0E6A5B9-4EA8-4AAC-A3F2-4ABF774409E7 Q27851455-89BC65D1-A12D-492B-9D93-28BEAAE2B0D5 Q28082908-5BB5DAB6-44A3-4535-9168-0A1F6E95EDCE Q28755868-B093FB54-687E-4EFF-8347-81BAF3B809B7 Q28828283-1DE42AD3-8521-4DF2-AFFC-6A37B2E32E80 Q30429122-804AD17E-EF33-4E3A-A826-EFADA314F03C Q30560557-4080AAB9-5683-40E0-94E6-70A2027A3D3B Q30653607-5C594213-CEEC-4AC1-9173-9957408C3DD6 Q33279184-3492206E-DD2C-4029-AC75-38D3746433F6 Q33442594-0C248857-FE35-4F9E-BD1B-FFB56E385054 Q33457195-5EA9F13A-2CE9-4989-97C6-F6104BD4BE99 Q33563488-B8077488-5E6D-44F3-B2C9-3D74FC73093C Q33587106-7EA6C9C1-6C86-4D15-AA98-AC5FC21C1AB8 Q33597254-5F3E3FE5-137E-4D7D-A129-01DE5E4D873A Q33688219-56535EE8-EA7D-4422-B7DF-F5C830DFF4F3 Q33730122-DED04C1C-046A-4626-8749-FF4F3AC17743 Q33732486-5EBC64D5-0516-4E81-B2FE-00B9888F3515 Q33770680-2958CB1D-EC2B-47D2-A782-6076A35DE363 Q33920800-0BC15654-53EB-43D4-ACCD-455DAD9E4EF2 Q33922534-BC053AB0-9D59-4C94-AB8A-7677247AE3E7 Q33926377-277AC045-C2FC-4E42-AFF2-04157F435495 Q34206601-8F5F25F4-E2F5-426A-A509-24DB5E17DF81 Q34268162-FE2FEC8E-90DB-4C32-A675-D424AE2DCB77 Q34343317-B874256D-CD67-4062-9994-FCBB5AECC8AC Q34389368-09647A34-7D2F-4C30-82AA-F391F30A04E5 Q34393461-6FD9A8CD-6CB3-43F1-B953-64999652DB46 Q34589774-58EB9029-5DA0-4310-85A3-EB9EE18263C5

P2860

Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.

http://www.wikidata.org/entity/Q44680981

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

Combined inhibition of VEGF an ...... lial cell survival mechanisms.

@en

Combined inhibition of VEGF an ...... lial cell survival mechanisms.

@nl

type

label

Combined inhibition of VEGF an ...... lial cell survival mechanisms.

@en

Combined inhibition of VEGF an ...... lial cell survival mechanisms.

@nl

prefLabel

Combined inhibition of VEGF an ...... lial cell survival mechanisms.

@en

Combined inhibition of VEGF an ...... lial cell survival mechanisms.

@nl

P1433

Q44680981-25C2C652-9C86-4F92-BA2C-3FDF256027E9

P1476

Q44680981-3CB0E21C-035F-4FFE-87A3-A56AB5033356

P2093

Q44680981-00928B6A-4165-4248-B957-F7BB0407049F

Q44680981-091B3F2A-D141-4B35-9659-7163D1E2AF2D

Q44680981-2C745D2B-BC67-4CB2-84AC-4C92829D0797

Q44680981-6F542D3E-5232-439B-B1BC-2CE70011174E

Q44680981-80736895-5E46-4A69-8F3B-B56EAC0203D4

Q44680981-8B7FC4BD-CA18-4E9B-B3F8-BF8F919C7DF2

Q44680981-94356F6E-4208-479A-B995-392E5C6E96F8

Q44680981-C93D9E5E-5D88-4DDE-BE74-2029B33F45B8

Q44680981-D23961CC-7332-4D60-9B28-E7E88B932FE5

P304

Q44680981-CCDD58B6-76A8-41C3-9D94-103DE1326D57

P31

Q44680981-0397BD84-D001-4266-BE58-225876688C4C

P356

Q44680981-109A30DC-A57C-4FBD-885F-57810C99BDB5

P407

Q44680981-6337853F-73F9-4113-9E5B-97A01BCC61EC

P433

Q44680981-4CEB2D8A-CF1D-4230-9389-3F82359F8796

P478

Q44680981-E9CEC306-6D1D-43F4-B8FD-4F88317D465D

P577

Q44680981-9D36B4A0-3D85-4337-A5CA-F79D0FB2AEF8

P5875

Q44680981-4F6E98A5-4053-45ED-BF40-F05DDDDC85A6

P698

Q44680981-AB2C9063-CAB0-430A-9ECB-8D0C1C754A98

P921

Q44680981-E1165486-85BE-45C6-BD60-811F21FA19A0

Q44680981-F4AFA25D-F9F0-4748-894C-5FC773F37F4A

P356

P1433

P1476

Combined inhibition of VEGF an ...... lial cell survival mechanisms.

@en

P2093

Alice D Katsen

http://www.w3.org/2001/XMLSchema#string

Andreas Thurnher

http://www.w3.org/2001/XMLSchema#string

Axel Ullrich

http://www.w3.org/2001/XMLSchema#string

Gesine Groth

http://www.w3.org/2001/XMLSchema#string

Hans-Peter Hammes

http://www.w3.org/2001/XMLSchema#string

Heinz Kerger

http://www.w3.org/2001/XMLSchema#string

Michael D Menger

http://www.w3.org/2001/XMLSchema#string

Peter Vajkoczy

http://www.w3.org/2001/XMLSchema#string

Ralf Erber

http://www.w3.org/2001/XMLSchema#string

P304

338-340

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1096/FJ.03-0271FJE

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2003-12-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8975009

http://www.w3.org/2001/XMLSchema#string

P698

14657001

http://www.w3.org/2001/XMLSchema#string

P921